Impact of Dual Antithrombotic Therapy with Aspirin and Rivaroxaban on Secondary Cardiovascular Outcomes
Medical Science Monitor · 2024
DOI: 10.12659/msm.945457 ↗Kurz gefasst
Fachartikel in der Zeitschrift Medical Science Monitor, 2024. Verfasst von Wei Li und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China. Hauptthemen laut MEDLINE: Rivaroxaban, Aspirin, Secondary Prevention. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Cardiovascular, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
- Department of Cardiovascular Medicine, The Second Hospital of Hebei Medical University, Shijiazhuang, Hebei, China.
Zitieren
APA
Li, W., Li, Y., Liu, C., Yuan, J., Fan, W., Miao, Q., & Gu, X. (2024). Impact of Dual Antithrombotic Therapy with Aspirin and Rivaroxaban on Secondary Cardiovascular Outcomes. Medical Science Monitor. https://doi.org/10.12659/msm.945457
Vancouver
Li W, Li Y, Liu C, Yuan J, Fan W, Miao Q, et al. Impact of Dual Antithrombotic Therapy with Aspirin and Rivaroxaban on Secondary Cardiovascular Outcomes. Medical Science Monitor. 2024. doi:10.12659/msm.945457
BibTeX
@article{Li2024,
author = {Li, Wei and Li, Yi and Liu, Chen and Yuan, Jinghao and Fan, Weize and Miao, Qing and Gu, Xinshun},
title = {Impact of Dual Antithrombotic Therapy with Aspirin and Rivaroxaban on Secondary Cardiovascular Outcomes},
journal = {Medical Science Monitor},
year = {2024},
doi = {10.12659/msm.945457}
}
EUVIMED